P2RX7 and neoplasm: On the contrary, ATP levels remain unaltered in the TME of mice treated with the P2X7 antagonist, due to increased release of ATP from tumor cells and decreased ectonucleotidase expression, with a net result of a robust tumor inhibition owing to combined immune effect and direct action on tumor cells’ P2X7.